Treatment of classical Kaposi's sarcoma with gemcitabine

Lucia Brambilla, Roberto Labianca, Silvia M. Ferrucci, Michela Taglioni, Vinicio Boneschi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Several drugs are active in aggressive classical Kaposi's sarcoma (CKS); chemotherapeutic agents with fewer side-effects, more rapid response and able to overcome resistance to previous treatment are advisable when treating patients in a second line. Gemcitabine, an analogue of deoxycytidine with cytotoxic activity in the treatment of solid tumours, has been found to have no serious side-effects. Objective: To evaluate the usefulness of treating patients affected by aggressive CKS with gemcytabine. Methods: Twelve patients with a recurrent aggressive form of CKS previously treated with chemotherapy were treated with gemcitabine. The drug was administered intravenously at the dose of 1.2 g/week for 2 weeks, followed by a 1-week interval, until maximal response was reached. Objective responses and toxicity were evaluated according to WHO criteria. Results: Eleven evaluable patients achieved an objective response: CR in 1/11 and PR in 10/11. Toxicity was limited. Conclusion: This study shows the usefulness of treating patients affected with aggressive CKS with gemcitabine, in order to obtain control of the disease and to reduce the related symptoms as well as to overcome a possible resistance to previous treatments.

Original languageEnglish
Pages (from-to)119-122
Number of pages4
JournalDermatology
Volume202
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

gemcitabine
Kaposi's Sarcoma
Therapeutics
Deoxycytidine
Pharmaceutical Preparations
Drug Therapy

Keywords

  • Chemotherapy
  • Classical Kaposi's sarcoma
  • Gemcitabine

ASJC Scopus subject areas

  • Dermatology

Cite this

Treatment of classical Kaposi's sarcoma with gemcitabine. / Brambilla, Lucia; Labianca, Roberto; Ferrucci, Silvia M.; Taglioni, Michela; Boneschi, Vinicio.

In: Dermatology, Vol. 202, No. 2, 2001, p. 119-122.

Research output: Contribution to journalArticle

Brambilla, Lucia ; Labianca, Roberto ; Ferrucci, Silvia M. ; Taglioni, Michela ; Boneschi, Vinicio. / Treatment of classical Kaposi's sarcoma with gemcitabine. In: Dermatology. 2001 ; Vol. 202, No. 2. pp. 119-122.
@article{3220a52e64234673916de3589833555a,
title = "Treatment of classical Kaposi's sarcoma with gemcitabine",
abstract = "Background: Several drugs are active in aggressive classical Kaposi's sarcoma (CKS); chemotherapeutic agents with fewer side-effects, more rapid response and able to overcome resistance to previous treatment are advisable when treating patients in a second line. Gemcitabine, an analogue of deoxycytidine with cytotoxic activity in the treatment of solid tumours, has been found to have no serious side-effects. Objective: To evaluate the usefulness of treating patients affected by aggressive CKS with gemcytabine. Methods: Twelve patients with a recurrent aggressive form of CKS previously treated with chemotherapy were treated with gemcitabine. The drug was administered intravenously at the dose of 1.2 g/week for 2 weeks, followed by a 1-week interval, until maximal response was reached. Objective responses and toxicity were evaluated according to WHO criteria. Results: Eleven evaluable patients achieved an objective response: CR in 1/11 and PR in 10/11. Toxicity was limited. Conclusion: This study shows the usefulness of treating patients affected with aggressive CKS with gemcitabine, in order to obtain control of the disease and to reduce the related symptoms as well as to overcome a possible resistance to previous treatments.",
keywords = "Chemotherapy, Classical Kaposi's sarcoma, Gemcitabine",
author = "Lucia Brambilla and Roberto Labianca and Ferrucci, {Silvia M.} and Michela Taglioni and Vinicio Boneschi",
year = "2001",
doi = "10.1159/000051610",
language = "English",
volume = "202",
pages = "119--122",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Treatment of classical Kaposi's sarcoma with gemcitabine

AU - Brambilla, Lucia

AU - Labianca, Roberto

AU - Ferrucci, Silvia M.

AU - Taglioni, Michela

AU - Boneschi, Vinicio

PY - 2001

Y1 - 2001

N2 - Background: Several drugs are active in aggressive classical Kaposi's sarcoma (CKS); chemotherapeutic agents with fewer side-effects, more rapid response and able to overcome resistance to previous treatment are advisable when treating patients in a second line. Gemcitabine, an analogue of deoxycytidine with cytotoxic activity in the treatment of solid tumours, has been found to have no serious side-effects. Objective: To evaluate the usefulness of treating patients affected by aggressive CKS with gemcytabine. Methods: Twelve patients with a recurrent aggressive form of CKS previously treated with chemotherapy were treated with gemcitabine. The drug was administered intravenously at the dose of 1.2 g/week for 2 weeks, followed by a 1-week interval, until maximal response was reached. Objective responses and toxicity were evaluated according to WHO criteria. Results: Eleven evaluable patients achieved an objective response: CR in 1/11 and PR in 10/11. Toxicity was limited. Conclusion: This study shows the usefulness of treating patients affected with aggressive CKS with gemcitabine, in order to obtain control of the disease and to reduce the related symptoms as well as to overcome a possible resistance to previous treatments.

AB - Background: Several drugs are active in aggressive classical Kaposi's sarcoma (CKS); chemotherapeutic agents with fewer side-effects, more rapid response and able to overcome resistance to previous treatment are advisable when treating patients in a second line. Gemcitabine, an analogue of deoxycytidine with cytotoxic activity in the treatment of solid tumours, has been found to have no serious side-effects. Objective: To evaluate the usefulness of treating patients affected by aggressive CKS with gemcytabine. Methods: Twelve patients with a recurrent aggressive form of CKS previously treated with chemotherapy were treated with gemcitabine. The drug was administered intravenously at the dose of 1.2 g/week for 2 weeks, followed by a 1-week interval, until maximal response was reached. Objective responses and toxicity were evaluated according to WHO criteria. Results: Eleven evaluable patients achieved an objective response: CR in 1/11 and PR in 10/11. Toxicity was limited. Conclusion: This study shows the usefulness of treating patients affected with aggressive CKS with gemcitabine, in order to obtain control of the disease and to reduce the related symptoms as well as to overcome a possible resistance to previous treatments.

KW - Chemotherapy

KW - Classical Kaposi's sarcoma

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=0035061137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035061137&partnerID=8YFLogxK

U2 - 10.1159/000051610

DO - 10.1159/000051610

M3 - Article

C2 - 11306832

AN - SCOPUS:0035061137

VL - 202

SP - 119

EP - 122

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 2

ER -